Ebronucimab

Cat. No. M40600

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

Ebronucimab is a monoclonal antibody to PCSK9 that can be used in studies related to hypercholesterolemia.

CAS Number	2304800-90-4
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related PCSK9 Products
PCSK9-IN-13 PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM.
PCSK9 ligand 1 PCSK9 ligand 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) ligand.
AZD0780 AZD0780 (PCSK9-IN-12, EX-A6975) is an oral, potentially first-in-class small molecule inhibitor of PCSK9. AZD0780 (PCSK9-IN-12, EX-A6975) has bind affinity for PCSK9 with a Kd value of ＜200 nM. AZD0780 (PCSK9-IN-12, EX-A6975) can be used for the research of cholesterol metabolism.
NNC0385-0434 NNC0385-0434 is a peptide based on the epidermal growth-factor-like domain A of the human LDLR peptide. NNC0385-0434 competitively binds free PCSK9 and subsequently prevents PCSK9 binding to the LDLR. NNC0385-0434 is an orally active peptide small molecule PCSK9 inhibitor for atherosclerosis-related studies.
CiVi-008 CiVi-008 is an orally active PCSK9 antisense oligonucleotide (ASO) inhibitor for studies related to disorders of lipid metabolism.

Catalog